Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir

Antiviral Therapy

Volumn 6, Issue 3, 2001, Pages 185-189

  Yerly, S ^a   Rickenbach, M ^a   Popescu, M ^a   Taffe, P ^a   Craig, C ^a   Perrin, L ^a   Battegay, M ^a   Bernard, M C ^a   Bernasconi, E ^a   Bucher, H ^a   Burgisser Ph ^a   Egger, M ^a   Erb, P ^a   Fierz, W ^a   Flepp, M ^a   Francioli, P ^a   Furrer, H J ^a   Gorgievski, M ^a   Gunthard H ^a   Grob, P ^a   Hirschel, B ^a   Kind, C ^a   Klimkait, T ^a   Ledergerber, B ^a   Lauper, U ^a   Opravil, M ^a   Paccaud, F ^a   Pantaleo, G ^a   Piffaretti, J C ^a   Rudin, C ^a   Schupbach, J ^a   Telenti, A ^a   Vernazza, P ^a   Wagels, T ^a   Weber, R ^a   more..

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; COHORT ANALYSIS; DATA BASE; DRUG RESPONSE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWITZERLAND; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MOLECULAR SEQUENCE DATA; MUTATION; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0035659914     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Impact of new antiretroviral combination therapies in HIV infected subjects in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
3. Hidden dangers of incompletely suppressive antiretroviral therapy
4. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors
5. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance
6. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
7. Antiviral resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
8. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
9. Phenotypic resistance testing significantly improves response to therapy (Tx): A randomized trial (VIRA 3001)
10. Transmission of antiretroviral-drug-resistant HIV-1 variants
11. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics
12. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
13. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
14. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team)
15. Nelfinavir: An update on its use in HIV infection